Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julian Nam

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
International Journal of Stroke : Official Journal of the International Stroke Society|January 9, 2013
Intra-arterial thrombolysis vs. standard treatment or intravenous thrombolysis in adults with acute ischemic stroke: a systematic review and meta-analysisJulian Nam, He Jing, Daria O'Reilly
Medical Decision Making : an International Journal of the Society for Medical Decision Making|June 10, 2016
Bayesian Solutions for Handling Uncertainty in Survival ExtrapolationMiguel A Negrín, Julian Nam, Andrew H Briggs
Annals of Emergency Medicine|December 26, 2013
Systematic review and meta-analysis of the benefits of out-of-hospital 12-lead ECG and advance notification in ST-segment elevation myocardial infarction patientsJulian Nam, Kyla Caners, James M Bowen, et al.
Current Oncology (Toronto, Ont.)|December 23, 2021
Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) PatientsYuti P Patel, Donald Husereau, Natasha B Leighl, et al.
Journal of Medical Economics|August 25, 2017
Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemiaJulian Nam, Robert Milenkovski, Simon Yunger, et al.
Journal of Medical Economics|June 30, 2020
Costs of in-house genomic profiling and implications for economic evaluation: a case example of non-small cell lung cancer (NSCLC)Karissa M Johnston, Brandon S Sheffield, Stephen Yip, et al.
Pharmacogenomics|April 18, 2020
Cost-effectiveness of combinatorial pharmacogenomic testing for depression from the Canadian public payer perspectiveJulie-Anne Tanner, Paige E Davies, Christopher C Overall, et al.
Advances in Therapy|May 5, 2024
Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type 1 Spinal Muscular AtrophyChristos Kokaliaris, Rachel Evans, Neil Hawkins, et al.
Journal of Medical Economics|March 6, 2019
Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)Umang Ondhia, H J Conter, Scott Owen, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 5, 2025
Economic evaluation of next-generation sequencing technologies in pediatric patient groups with confirmed or possible rare diseases: A systematic literature reviewMarianna De Stefano, Rudolf van Olden, Elnaz Arjmand, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
International Journal of Stroke : Official Journal of the International Stroke Society|January 9, 2013
Intra-arterial thrombolysis vs. standard treatment or intravenous thrombolysis in adults with acute ischemic stroke: a systematic review and meta-analysisJulian Nam, He Jing, Daria O'Reilly
Medical Decision Making : an International Journal of the Society for Medical Decision Making|June 10, 2016
Bayesian Solutions for Handling Uncertainty in Survival ExtrapolationMiguel A Negrín, Julian Nam, Andrew H Briggs
Annals of Emergency Medicine|December 26, 2013
Systematic review and meta-analysis of the benefits of out-of-hospital 12-lead ECG and advance notification in ST-segment elevation myocardial infarction patientsJulian Nam, Kyla Caners, James M Bowen, et al.
Current Oncology (Toronto, Ont.)|December 23, 2021
Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) PatientsYuti P Patel, Donald Husereau, Natasha B Leighl, et al.
Journal of Medical Economics|August 25, 2017
Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemiaJulian Nam, Robert Milenkovski, Simon Yunger, et al.
Journal of Medical Economics|June 30, 2020
Costs of in-house genomic profiling and implications for economic evaluation: a case example of non-small cell lung cancer (NSCLC)Karissa M Johnston, Brandon S Sheffield, Stephen Yip, et al.
Pharmacogenomics|April 18, 2020
Cost-effectiveness of combinatorial pharmacogenomic testing for depression from the Canadian public payer perspectiveJulie-Anne Tanner, Paige E Davies, Christopher C Overall, et al.
Advances in Therapy|May 5, 2024
Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type 1 Spinal Muscular AtrophyChristos Kokaliaris, Rachel Evans, Neil Hawkins, et al.
Journal of Medical Economics|March 6, 2019
Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)Umang Ondhia, H J Conter, Scott Owen, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 5, 2025
Economic evaluation of next-generation sequencing technologies in pediatric patient groups with confirmed or possible rare diseases: A systematic literature reviewMarianna De Stefano, Rudolf van Olden, Elnaz Arjmand, et al.
Pageof 2